We Published Guide for European Biotechs Entering the U.S. RNA Market - Part2

We published the second installment of his two-part guest column series with Advancing RNA, exploring how European biotech leaders can build lasting success in the U.S. market.

This final article moves beyond regulatory strategy to cover the financial and organisational decisions that matter most: U.S. fundraising and VC dynamics, pharma partnerships and licensing norms, nondilutive funding opportunities through NIH, BARDA, and ARPA-H, manufacturing and CDMO considerations, and the legal infrastructure needed to operate confidently in the U.S.

The article closes with hard-won lessons on common pitfalls, from hiring timing to cultural translation. Read the full piece here.